Tiziana Martino

Distinct Brain Volume Changes Correlating with Clinical Stage, Disease Progression Rate, Mutation Size, and Age at Onset Prediction as Early Biomarkers of Brain Atrophy in Huntington's Disease

Ferdinando Squitieri, Milena Cannella, Maria Simonelli et al. · CNS Neuroscience & Therapeutics · 2009 · 80 citations

Life Sciences, Neurology, Neuroscience +17

Riluzole protects Huntington disease patients from brain glucose hypometabolism and grey matter volume loss and increases production of neurotrophins

Ferdinando Squitieri, S. Orobello, Milena Cannella et al. · European Journal of Nuclear Medicine and Molecular Imaging · 2009 · 65 citations

Life Sciences, Neurology, Neuroscience +14

Clinical manifestations of intermediate allele carriers in Huntington disease

Esther Cubo, María A. Ramos-Arroyo, Saül Martínez‐Horta et al. · Neurology · 2016 · 54 citations

Life Sciences, Genetics, Neurology +13

Affinity purification of IgG monoclonal antibodies using the D-PAM synthetic ligand: chromatographic comparison with protein A and thermodynamic investigation of the D-PAM/IgG interaction

Biagio D'Agostino, Piero Bellofiore, Tiziana Martino et al. · Journal of Immunological Methods · 2008 · 43 citations

Pharmacy, Biochemistry, Immunology +17

Highly variable penetrance in subjects affected with cavernous cerebral angiomas (CCM) carrying novel CCM1 and CCM2 mutations

Fernando Gianfrancesco, Milena Cannella, Tiziana Martino et al. · American Journal of Medical Genetics Part B Neuropsychiatric Genetics · 2007 · 41 citations

Medicine, Molecular Genetics, Neurology +14